{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:36:27Z","timestamp":1791128187363,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research (CIHR)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.coviro.2012.08.004","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T07:30:20Z","timestamp":1347089420000},"page":"644-650","source":"Crossref","is-referenced-by-count":49,"title":["The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance"],"prefix":"10.1016","volume":"2","author":[{"given":"Matthias","family":"G\u00f6tte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2012.08.004_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the international antiviral society-USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.coviro.2012.08.004_bib0010","first-page":"156","article-title":"2011 update of the drug resistance mutations in HIV-1","volume":"19","author":"Johnson","year":"2011","journal-title":"Topics in Antiviral Medicine"},{"issue":"Suppl 1","key":"10.1016\/j.coviro.2012.08.004_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/gutjnl-2012-302144","article-title":"New direct-acting antiviral agents for the treatment of hepatitis c virus infection and perspectives","volume":"61","author":"Welsch","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2012.08.004_bib0020_1","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis c virus","volume":"2","author":"Rong","year":"2010","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.coviro.2012.08.004_bib0025","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1046\/j.1365-2516.1998.440610.x","article-title":"Resistance to HIV protease inhibitors","volume":"4","author":"Condra","year":"1998","journal-title":"Haemophilia: The Official Journal of the World Federation of Hemophilia"},{"key":"10.1016\/j.coviro.2012.08.004_bib0030","first-page":"69","article-title":"Genetic barriers to resistance and impact on clinical response","volume":"7","author":"Luber","year":"2005","journal-title":"MedGenMed: Medscape General Medicine"},{"key":"10.1016\/j.coviro.2012.08.004_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/095632020401500302","article-title":"Clinical utility of current nnrtis and perspectives of new agents in this class under development","volume":"15","author":"Zhang","year":"2004","journal-title":"Antiviral Chemistry & Chemotherapy"},{"key":"10.1016\/j.coviro.2012.08.004_bib0040","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1128\/JVI.75.16.7462-7469.2001","article-title":"Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients","volume":"75","author":"Kempf","year":"2001","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0045","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1128\/JVI.79.6.3329-3338.2005","article-title":"Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates","volume":"79","author":"Mo","year":"2005","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0050","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"Hiv-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.coviro.2012.08.004_bib0055","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1086\/430005","article-title":"Estimating HIV evolutionary pathways and the genetic barrier to drug resistance","volume":"191","author":"Beerenwinkel","year":"2005","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.08.004_bib0060","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1086\/651136","article-title":"Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy","volume":"201","author":"Metzner","year":"2010","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.08.004_bib0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","article-title":"Fifteen years of HIV protease inhibitors: raising the barrier to resistance","volume":"85","author":"Wensing","year":"2010","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.08.004_bib0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/1471-2105-11-409","article-title":"Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape","volume":"11","author":"Theys","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.coviro.2012.08.004_bib0075","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/01.qai.0000209899.05126.e4","article-title":"The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes","volume":"41","author":"van de Vijver","year":"2006","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"Suppl 2","key":"10.1016\/j.coviro.2012.08.004_bib0080","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/00126334-200310012-00002","article-title":"Preventing and managing resistance in the clinical setting","volume":"34","author":"Kuritzkes","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.coviro.2012.08.004_bib0085_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1473-3099(11)70314-0","article-title":"Selection of chronic hepatitis b therapy with high barrier to resistance","volume":"12","author":"Gish","year":"2012","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.08.004_bib0090","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis c virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0095_1","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis c virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"Powdrill","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.coviro.2012.08.004_bib0100_1","doi-asserted-by":"crossref","first-page":"e39652","DOI":"10.1371\/journal.pone.0039652","article-title":"Hcv genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors","volume":"7","author":"Cento","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.08.004_bib0105","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1128\/AAC.00294-11","article-title":"Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis c virus replication","volume":"55","author":"Delang","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.08.004_bib0110","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2460925","article-title":"The accuracy of reverse transcriptase from HIV-1","volume":"242","author":"Roberts","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.coviro.2012.08.004_bib0115","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.2460924","article-title":"Fidelity of HIV-1 reverse transcriptase","volume":"242","author":"Preston","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.coviro.2012.08.004_bib0120","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.1016\/S0021-9258(18)35706-5","article-title":"Mechanism and fidelity of HIV reverse transcriptase","volume":"267","author":"Kati","year":"1992","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.coviro.2012.08.004_bib0125","doi-asserted-by":"crossref","first-page":"14056","DOI":"10.1021\/bi971385+","article-title":"RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates","volume":"36","author":"Kerr","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.coviro.2012.08.004_bib0130","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jmb.2007.11.021","article-title":"Mechanistic insights into the role of val75 of HIV-1 reverse transcriptase in misinsertion and mispair extension fidelity of DNA synthesis","volume":"375","author":"Matamoros","year":"2008","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0135","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nri1489","article-title":"Retroviral restriction by apobec proteins","volume":"4","author":"Harris","year":"2004","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0140","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/infdis\/171.6.1411","article-title":"Rapid changes in human immunodeficiency virus type 1 rna load and appearance of drug-resistant virus populations in persons treated with lamivudine (3tc)","volume":"171","author":"Schuurman","year":"1995","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.08.004_bib0145","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/JVI.71.4.3346-3350.1997","article-title":"Initial appearance of the 184ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase","volume":"71","author":"Keulen","year":"1997","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0150","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1128\/JVI.74.14.6262-6268.2000","article-title":"Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection","volume":"74","author":"Frost","year":"2000","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0155","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1073\/pnas.0710190105","article-title":"Cytidine deamination induced HIV-1 drug resistance","volume":"105","author":"Mulder","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.coviro.2012.08.004_bib0160","doi-asserted-by":"crossref","first-page":"e1000367","DOI":"10.1371\/journal.ppat.1000367","article-title":"Likely role of apobec3g-mediated g-to-a mutations in HIV-1 evolution and drug resistance","volume":"5","author":"Jern","year":"2009","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.coviro.2012.08.004_bib0165","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/QAD.0b013e32833e515a","article-title":"Partially active HIV-1 vif alleles facilitate viral escape from specific antiretrovirals","volume":"24","author":"Fourati","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2012.08.004_bib0170","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/JVI.00056-10","article-title":"Apobec3g contributes to HIV-1 variation through sublethal mutagenesis","volume":"84","author":"Sadler","year":"2010","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0175","series-title":"Antiretroviral Resistance in Clinical Practice","article-title":"The impact of resistance on viral fitness and its clinical implications","author":"De Luca","year":"2006"},{"key":"10.1016\/j.coviro.2012.08.004_bib0180","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/j.1460-2075.1996.tb00777.x","article-title":"Reduced replication of 3tc-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme","volume":"15","author":"Back","year":"1996","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.coviro.2012.08.004_bib0185","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3851\/IMP2088","article-title":"Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent rna polymerase","volume":"17","author":"Pawlotsky","year":"2012","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.coviro.2012.08.004_bib0190","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/AAC.00444-08","article-title":"Selected replicon variants with low-level in vitro resistance to the hepatitis c virus ns5b polymerase inhibitor psi-6130 lack cross-resistance with r1479","volume":"52","author":"Ali","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.08.004_bib0195","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00433-06","article-title":"General catalytic deficiency of hepatitis c virus rna polymerase with an s282t mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues","volume":"50","author":"Dutartre","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.08.004_bib0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an hcv ns5a inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2012.08.004_bib0205","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis c virus ns5a inhibitor bms-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.08.004_bib0210","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic hcv genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.08.004_bib0215","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic hcv infection","volume":"360","author":"Hezode","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.08.004_bib0220","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A v106m mutation in HIV-1 clade c viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2012.08.004_bib0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1743-422X-8-149","article-title":"Hiv integrase variability and genetic barrier in antiretroviral naive and experienced patients","volume":"8","author":"Piralla","year":"2011","journal-title":"Virology Journal"},{"key":"10.1016\/j.coviro.2012.08.004_bib0230","doi-asserted-by":"crossref","first-page":"256982","DOI":"10.1155\/2012\/256982","article-title":"The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs","volume":"2012","author":"Wainberg","year":"2012","journal-title":"Molecular Biology International"},{"key":"10.1016\/j.coviro.2012.08.004_bib0235","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.dld.2011.07.002","article-title":"Role of hepatitis b virus genetic barrier in drug-resistance and immune-escape development","volume":"43","author":"Svicher","year":"2011","journal-title":"Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"key":"10.1016\/j.coviro.2012.08.004_bib0240","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/JVI.01349-08","article-title":"Template usage is responsible for the preferential acquisition of the k65r reverse transcriptase mutation in subtype c variants of human immunodeficiency virus type 1","volume":"83","author":"Coutsinos","year":"2009","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.08.004_bib0245","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of k65r for antiretroviral therapy-naive patients with subtype c HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2012.08.004_bib0250_1","doi-asserted-by":"crossref","first-page":"e20208","DOI":"10.1371\/journal.pone.0020208","article-title":"A template-dependent dislocation mechanism potentiates k65r reverse transcriptase mutation development in subtype c variants of HIV-1","volume":"6","author":"Coutsinos","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.08.004_bib0255","doi-asserted-by":"crossref","first-page":"e1002368","DOI":"10.1371\/journal.pcbi.1002368","article-title":"Dynamic energy landscapes of riboswitches help interpret conformational rearrangements and function","volume":"8","author":"Quarta","year":"2012","journal-title":"PLoS Computational Biology"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625712001307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625712001307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T13:58:35Z","timestamp":1643378315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625712001307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1879625712001307"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2012.08.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}